Sensus Healthcare, Inc.
SRTSSensus Healthcare, Inc. in brief
Sensus Healthcare, Inc. is a listed company in the Medical Devices industry, based in Boca Raton, Florida, USA. Its market value was $49 M on 1 October 2026, which makes it the 21,331st largest listed company in the world and the 3,862nd largest in the USA on this site. In the year to December 2025 it had sales of $27 M and a net loss of $8 M. It employs about 60 people and Joseph C. Sardano is its chief executive. Its largest product and service lines by sales in 2025 were Service Revenue (13%) and Product Revenue (6%). By market, the largest shares of its 2025 sales came from USA (92%) and China (7%). Its shares trade under the symbol SRTS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc. is a medical device company committed to providing highly effective, non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy, which is based on decades of dedicated research and development, and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions of close to one-million patients around the world.
From the company's annual report filed with the US SEC: read the report
Sensus Healthcare, Inc. timeline
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2015
- ✎Renamed Sensus Healthcare, Inc.Formerly Sensus Healthcare, LLC.
- 2016
- 🔔· approximateInitial public offering on Nasdaq
- 2022
- 💰Record revenue of $45 millionFY2022, the highest of the 8 years on record.
- 💰Record net income of $24 millionFY2022, the highest profit of the 4 years on record.
Events of Sensus Healthcare, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,032 (Jan 2020) · #3,942 (Jan 2021) · #4,171 (Jan 2022) · #4,152 (Dec 2022) · #4,763 (Jul 2023) · #4,146 (Jan 2024) · #2,048 (Mar 2026) · #3,753 (Aug 2026) · #3,843 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.8×
- Price / book
- 1.0×
- Free cash flow yield
- 0.7%
- Net margin (TTM)
- -88.5%
- Operating margin
- -37.5%
- Return on equity
- -32.2%
- Liabilities / assets
- 9.3%
- Revenue growth
- -34.3%
- R&D / revenue
- 28.3%
- Revenue per employee
- $458 K
- Profit per employee
- $-129 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $27M | -34.3% | $-10M | $-8M | -28.1% |
| Dec 2024 | $42M | +71.4% | $8M | $7M | 15.9% |
| Dec 2023 | $24M | -45.2% | $-0M | $0M | 2.0% |
| Dec 2022 | $45M | +64.7% | $15M | $24M | 54.4% |
| Dec 2021 | $27M | +182.3% | $4M | $4M | 15.2% |
| Dec 2020 | $10M | -64.9% | $-8M | $-7M | -71.4% |
| Dec 2019 | $27M | +3.1% | $-2M | $-2M | -6.2% |
| Dec 2018 | $26M | — | $-2M | $-2M | -7.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $1M | $0M | $0M | $-0.47 | — |
| Dec 2024 | $-1M | $0M | $-1M | $0.41 | — |
| Dec 2023 | $-2M | $0M | $-2M | $0.03 | — |
| Dec 2022 | $-1M | $0M | $-2M | $1.46 | — |
| Dec 2021 | $-0M | $0M | $-0M | $0.25 | — |
| Dec 2020 | $-0M | $0M | $-1M | $-0.42 | — |
| Dec 2019 | $-2M | $0M | $-3M | $-0.10 | — |
| Dec 2018 | $-9M | $1M | $-9M | $-0.14 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $6M (-12.8% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 5, 20268-KCurrent reportMaterial agreement
- Jun 2, 20268-KCurrent reportShareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Apr 29, 2026DEF 14AProxy statement
- Mar 4, 202610-KAnnual report · period to Dec 2025
- Feb 12, 20268-KCurrent reportResults of operations
- Jan 20, 20268-KCurrent reportAuditor change
- Jan 12, 20268-KCurrent reportDirectors or officers changed
Official filings of Sensus Healthcare, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $27 M
- Operating income
- $-10 M
- Net income
- $-8 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $53 M
- Total liabilities
- $5 M
- Total equity
- $48 M
As of December-2025
Top 37 institutional investors in Sensus Healthcare, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Pacific Ridge Capital Partners, LLC | 784,339 | -5,336 (-0.68%) | 4.76% | $2 M | Nov 12, 2026 |
| 2 | Vanguard Capital Management LLC | 660,402 | 0 (0.00%) | 4.01% | $2 M | Nov 13, 2026 |
| 3 | Dimensional Fund Advisors LP | 301,073 | -15,048 (-4.76%) | 1.83% | $1 M | Nov 4, 2026 |
| 4 | Divisadero Street Capital Management, LP | 278,485 | 0 (0.00%) | 1.69% | $1 M | Nov 16, 2026 |
| 5 | Renaissance Technologies LLC | 229,634 | -12,700 (-5.24%) | 1.39% | $1 M | Nov 12, 2026 |
| 6 | Geode Capital Management, LLC | 154,152 | 0 (0.00%) | 0.94% | $0 M | Nov 6, 2026 |
| 7 | Greenline Wealth Management LLC | 148,774 | +20,000 (+15.53%) | 0.90% | $0 M | Nov 10, 2026 |
| 8 | UBS Group AG | 143,146 | -9,427 (-6.18%) | 0.87% | $0 M | Nov 10, 2026 |
| 9 | North Star Investment Management Corp. | 125,586 | 0 (0.00%) | 0.76% | $0 M | Oct 27, 2026 |
| 10 | Bank of New York Mellon Corp | 101,646 | +1,236 (+1.23%) | 0.62% | $0 M | Nov 5, 2026 |
| 11 | Mindset Wealth Management, LLC | 86,000 | +33,900 (+65.07%) | 0.52% | $0 M | Oct 19, 2026 |
| 12 | BlackRock, Inc. | 81,420 | -2,135 (-2.56%) | 0.49% | $0 M | Nov 13, 2026 |
| 13 | Vanguard Fiduciary Trust Co | 76,289 | 0 (0.00%) | 0.46% | $0 M | Nov 13, 2026 |
| 14 | Allworth Financial LP | 69,880 | New | 0.42% | $0 M | Nov 17, 2026 |
| 15 | State Street Corp | 69,252 | 0 (0.00%) | 0.42% | $0 M | Nov 12, 2026 |
| 16 | Ingalls & Snyder LLC | 55,000 | 0 (0.00%) | 0.33% | $0 M | Nov 12, 2026 |
| 17 | Janney Montgomery Scott LLC | 40,576 | 0 (0.00%) | 0.25% | $0 M | Nov 12, 2026 |
| 18 | Chapin Davis, Inc. | 36,000 | +10,000 (+38.46%) | 0.22% | $0 M | Oct 9, 2026 |
| 19 | Citadel Advisors LLC | 30,391 | New | 0.18% | $0 M | Nov 16, 2026 |
| 20 | Northern Trust Corp | 28,187 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 21 | American Century Companies Inc | 21,272 | 0 (0.00%) | 0.13% | $0 M | Nov 12, 2026 |
| 22 | IMC-Chicago, LLC | 17,742 | New | 0.11% | $0 M | Nov 5, 2026 |
| 23 | Ashton Thomas Private Wealth, LLC | 16,828 | +521 (+3.19%) | 0.10% | $0 M | Nov 3, 2026 |
| 24 | Cetera Investment Advisers | 16,000 | New | 0.10% | $0 M | Nov 13, 2026 |
| 25 | StoneX Group Inc. | 13,151 | -227 (-1.70%) | 0.08% | $0 M | Nov 3, 2026 |
Show all 37: investors 26 to 37
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Rockefeller Capital Management L.P. | 7,000 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 27 | Vanguard Global Advisers, LLC | 4,961 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 28 | Morgan Stanley | 4,267 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 29 | Barclays PLC | 3,440 | +654 (+23.47%) | 0.02% | $0 M | Nov 6, 2026 |
| 30 | Jones Financial Companies Lllp | 1,275 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 31 | Osaic Holdings, Inc. | 1,196 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 32 | Farther Finance Advisors, LLC | 1,081 | 0 (0.00%) | 0.01% | $0 M | Oct 8, 2026 |
| 33 | Tower Research Capital LLC (TRC) | 997 | -27 (-2.64%) | 0.01% | $0 M | Nov 16, 2026 |
| 34 | Larson Financial Group LLC | 800 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 35 | Nuveen, LLC | 418 | New | 0.00% | $0 M | Nov 10, 2026 |
| 36 | FMR LLC | 155 | +6 (+4.03%) | 0.00% | $0 M | Nov 10, 2026 |
| 37 | SBI Securities Co., Ltd. | 13 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding Sensus Healthcare, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 494,131 | $1 M | 3.0% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Adara Smaller Companies FundRBB Fund, Inc. | 310,940 | $1 M | 1.9% | 0.12% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 154,670 | $0 M | 0.94% | <0.01% | +8.5% | Jun 30, 2026 |
| 🇺🇸 North Star Micro Cap FundNorth Star Investment Management Corp. | 125,586 | $0 M | 0.76% | 0.21% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 77,130 | $0 M | 0.47% | <0.01% | +3.5% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 75,124 | $0 M | 0.46% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 46,361 | $0 M | 0.28% | <0.01% | +36% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Value PortfolioDimensional Fund Advisors LP | 45,206 | $0 M | 0.27% | <0.01% | −21% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 29,133 | $0 M | 0.18% | <0.01% | −48% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Small Cap Value ETFDimensional Fund Advisors LP | 28,566 | $0 M | 0.17% | <0.01% | −58% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 24,723 | $0 M | 0.15% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 22,487 | $0 M | 0.14% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 20,910 | $0 M | 0.13% | <0.01% | +6.5% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 21,580 | $0 M | 0.13% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 20,030 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 13,502 | $0 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 11,601 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 11,506 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 10,687 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 7,608 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 4,620 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 3,395 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 3,049 | $0 M | 0.02% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 3,100 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 2,400 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 2,267 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 1,770 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 1,242 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 4 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 29 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Sensus Healthcare, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Joseph C. SardanoCHIEF EXECUTIVE OFFICER, Director | Buy | +30,000 | $2.404 | $72 K | 1.25 M | Form 4 |
| filed | Eric SachettaDirector | Buy | +27,304 | $3.540 | $97 K | 294,784 | Form 4 |
| filed | Eric SachettaDirector | Buy | +37,537 | $3.440 | $129 K | 267,480 | Form 4 |
| filed | Eric SachettaDirector | Buy | +10,925 | $3.180 | $35 K | 229,943 | Form 4 |
| filed | Eric SachettaDirector | Buy | +9,708 | $3.290 | $32 K | 219,018 | Form 4 |
| filed | Eric SachettaDirector | Buy | +34,697 | $3.250 | $113 K | 209,310 | Form 4 |
| filed | Eric SachettaDirector | Buy | +7,000 | $3.250 | $23 K | 174,613 | Form 4 |
| filed | Eric SachettaDirector | Buy | +24,000 | $3.130 | $75 K | 167,613 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Sensus Healthcare, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 241.95-for-1 split in the period to ; 241.95-for-1 split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2025 | Q4 2025 | $0M |
| Q3 2025 | Q3 2025 | $0M |
| Q2 2025 | Q2 2025 | $0M |
| Q1 2025 | Q1 2025 | $0.3M |
| Q4 2023 | Q4 2023 | $0M |
| Q4 2022 | Q4 2022 | $2M |
| Q3 2022 | Q3 2022 | $0M |
Trading halts
- 2026-11-04 14:50 UTC, code LUDP, resumed 14:55 UTC
- 2026-11-04 14:37 UTC, code LUDP, resumed 14:49 UTC
- 2026-11-04 14:31 UTC, code LUDP, resumed 14:36 UTC
- 2026-11-03 16:40 UTC, code LUDP, resumed 16:50 UTC
Fails to deliver
- : 346 shares at $2.99
- : 856 shares at $3.07
- : 42 shares at $3.00
- : 206 shares at $2.94
- : 41 shares at $3.07
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Sensus Healthcare, Inc. scorecard#
Passes 5 of the 22 checks that could be worked out: strongest in financial health (2 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 1, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.0×Price to book 1.0× against Medical Devices's median of 2.5×.
- ✗Price to sales below its peers' median2.8×Price to sales 2.8× against Medical Devices's median of 2.4×.
- ✗Free cash flow yield above 5%0.7%Free cash flow is 0.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 6
- ✗Revenue grew in the newest year-34.3%Revenue down 34.3% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-14.9%-14.9% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-14.9%-14.9% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-0.47 vs 0.41Diluted EPS -0.47 in fiscal 2025 against 0.41 the year before (report's currency).
- ✗Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$7 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
- ✗Profitable in each of the last five years4 of 5Profitable in 4 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-37.5%-37.5% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-14.9%-14.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-37.5%-37.5% in fiscal 2025 against 33.3% in 2022.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities9.7×Current ratio 9.72 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone6.94Z-score 6.94 (safe zone) for fiscal 2025.
Shareholder returns2 of 3
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-0.2%Diluted shares down 0.2% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.6%Dividends and buybacks were 0.6% of the market value.
- ✓Free cash flow covers dividends and buybacks$0 MFree cash flow $0 M against $0 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Sensus Healthcare, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -37.5% | -8.2% | |
| Net margin | -28.1% | -10.4% | |
| Return on equity | -14.9% | -16.8% | |
| Revenue growth, 3 years a year | -14.9% | 10.8% | |
| Revenue growth | -34.3% | 10.4% | |
| Free cash flow margin | 1.2% | -1.9% |
4of 8on the Piotroski tests of financial strength
- Revenue fell 34.3% against the year before.
- Net loss of $8 million.
Sensus Healthcare, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 27,482−34.3%100% | 41,807+71.3%100% | 24,405−45.2%100% | 44,532+64.7%100% | 27,042+182%100% | 9,577r9,577−64.9%100% | 27,263+3.2%100% | 26,427+28.4%100% | 20,588+39.0%100% | 14,811—100% | |
| Cost of revenue | 15,615−10.1%56.8% | 17,376+68.0%41.6% | 10,345−30.6%42.4% | 14,904+48.2%33.5% | 10,054+132%37.2% | 4,328r4,328−55.4%45.2% | 9,706+2.0%35.6% | 9,516+40.2%36.0% | 6,788+36.7%33.0% | 4,965—33.5% | |
| Gross profit | 11,867−51.4%43.2% | 24,431+73.8%58.4% | 14,060−52.5%57.6% | 29,628+74.4%66.5% | 16,988+224%62.8% | 5,249r5,249−70.1%54.8% | 17,557+3.8%64.4% | 16,911+22.5%64.0% | 13,800+40.2%67.0% | 9,846—66.5% | |
| Research and development | 7,778+84.5%28.3% | 4,216+14.6%10.1% | 3,678+6.3%15.1% | 3,460+0.7%7.8% | 3,436−17.4%12.7% | 4,158r4,157−35.2%43.4% | 6,418+2.5%23.5% | 6,260+14.0%23.7% | 5,490+201%26.7% | 1,824—12.3% | |
| Selling, general and administrative | 7,873+10.2%28.6% | 7,147+38.6%17.1% | 5,156—21.1% | — | — | — | — | — | — | — | |
| Selling and marketing | 6,523+31.0%23.7% | 4,978−11.2%11.9% | 5,608−11.4%23.0% | 6,329+30.8%14.2% | 4,838−9.3%17.9% | 5,336r5,336−41.4%55.7% | 9,103+6.7%33.4% | 8,532+2.7%32.3% | 8,305+69.0%40.3% | 4,915—33.2% | |
| General and administrative | — | — | 5,156+3.0%21.1% | 5,008+9.0%11.2% | 4,594+15.2%17.0% | 3,989r3,989−0.4%41.7% | 4,005−2.9%14.7% | 4,124+10.8%15.6% | 3,722+7.3%18.1% | 3,469—23.4% | |
| Operating expenses | 22,174+35.7%80.7% | 16,341+13.1%39.1% | 14,442−2.4%59.2% | 14,797+15.0%33.2% | 12,868−4.6%47.6% | 13,483r13,483−30.9%141% | 19,525+3.2%71.6% | 18,916+8.0%71.6% | 17,517+71.6%85.1% | 10,209—68.9% | |
| Operating income | −10,307−227%−37.5% | 8,090—19.4% | −382−103%−1.6% | 14,831+260%33.3% | 4,120—15.2% | −8,234r−8,234—−86.0% | −1,968—−7.2% | −2,005—−7.6% | −3,717—−18.1% | −363—−2.5% | |
| Interest expense and finance costs | — | −932—−2.2% | −992—−4.1% | −380r2.0−19100%−0.9% | 2.0−85.7%0.0% | 14r14—0.1% | — | 157+127%0.6% | 69+215%0.3% | 22—0.1% | |
| Net interest income | 683−26.7%2.5% | 932—2.2% | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | 683−26.7%2.5% | 932−9.9%2.2% | 1,034−92.1%4.2% | 13,159—29.5% | −1.0−100%−0.0% | 1,398r1,398+421%14.6% | 268—1.0% | −17−351%−0.1% | 6.9−58.5%0.0% | 17—0.1% | |
| Income before tax | −9,624−207%−35.0% | 9,022+1284%21.6% | 652−97.7%2.7% | 27,990+580%62.9% | 4,119—15.2% | — | — | — | — | −346—−2.3% | |
| Income tax | −1,905−180%−6.9% | 2,375+1322%5.7% | 167−95.5%0.7% | 3,746—8.4% | — | — | — | — | — | — | |
| Net income attributable to shareholders | −7,719−216%−28.1% | 6,647+1271%15.9% | 485−98.0%2.0% | 24,244+489%54.4% | 4,119—15.2% | −6,836r−6,836—−71.4% | −1,700—−6.2% | −2,023—−7.7% | −3,711—−18.0% | −346—−2.3% | |
| Earnings per share, basic | -0.47−215%— | 0.41+1267%— | 0.03−98.0%— | 1.47+488%— | 0.25—— | -0.42—— | -0.10—— | -0.14—— | -0.28—— | -0.03—— | |
| Earnings per share, diluted | -0.47−215%— | 0.41+1267%— | 0.03−97.9%— | 1.46+484%— | 0.25—— | -0.42—— | -0.10—— | -0.14—— | -0.28—— | -0.03—— | |
| Shares, weighted average (basic) | 16+0.1%— | 16+0.3%— | 16−1.3%— | 16+0.0%— | 16+0.3%— | 16—— | — | — | — | — | |
| Shares, weighted average (diluted) | 16−0.2%— | 16+0.6%— | 16−2.1%— | 17+0.7%— | 17+0.4%— | 16+1.2%— | 16+15.0%— | 14+6.6%— | 13+10.0%— | 12—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 22,083+0.1%41.6% | 22,056−4.7%35.5% | 23,148−9.3%43.1% | 25,520+75.8%45.0% | 14,519−2.6%45.0% | 14,907r14,907+84.0%53.2% | 8,100r8,100−35.1%21.9% | 12,484+23.8%37.5% | 10,085+100%53.5% | 5,042—26.6% | |
| Receivables | 6,041−69.4%11.4% | 19,731+85.4%31.7% | 10,645−38.5%19.8% | 17,299+42.6%30.5% | 12,130+221%37.6% | 3,776r3,776−73.1%13.5% | 14,011+6.6%37.9% | 13,146+165%39.5% | 4,958+60.0%26.3% | 3,099—16.4% | |
| Inventory | 14,563+44.2%27.5% | 10,097−14.9%16.2% | 11,861+239%22.1% | 3,501+99.0%6.2% | 1,759−60.3%5.5% | 4,427r4,427+47.7%15.8% | 2,997+84.0%8.1% | 1,629+39.1%4.9% | 1,171−6.7%6.2% | 1,255—6.6% | |
| Other current assets | 1,683+11.7%3.2% | 1,507+69.7%2.4% | 888+34.5%1.7% | 660r538+146%1.2% | 268r2,837−87.0%0.8% | 2,061r2,061+36.9%7.4% | 1,505−14.0%4.1% | 1,751+209%5.3% | 567−37.1%3.0% | 901—4.8% | |
| Current assets | 45,892−19.1%86.5% | 56,738+14.6%91.3% | 49,528−7.0%92.2% | 53,241+70.4%93.8% | 31,245+24.1%96.9% | 25,171r25,171−26.0%89.9% | 34,003+6.6%92.1% | 31,902+78.4%95.9% | 17,887+6.7%95.0% | 16,759—88.5% | |
| Property, plant and equipment | 1,976−1.1%3.7% | 1,997+330%3.2% | 464+90.9%0.9% | 243−59.8%0.4% | 605−55.4%1.9% | 1,356r1,356+25.3%4.8% | 1,082+21.5%2.9% | 891+126%2.7% | 394−9.1%2.1% | 433—2.3% | |
| Right-of-use (leased) assets | 452−22.2%0.9% | 581−24.9%0.9% | 774−22.3%1.4% | 996+489%1.8% | 169−84.3%0.5% | 1,076r1,076−23.1%3.8% | 1,400—3.8% | 0—0.0% | — | — | |
| Other intangible assets | — | — | — | 50−65.8%0.1% | 146−56.8%0.5% | 338r338+0.2%1.2% | 337−22.2%0.9% | 434−18.2%1.3% | 530−15.4%2.8% | 627—3.3% | |
| Total assets | 53,039−14.7%100% | 62,165+15.7%100% | 53,710−5.3%100% | 56,735+76.0%100% | 32,240+15.1%100% | 28,010r28,010−24.1%100% | 36,925+11.0%100% | 33,251+76.5%100% | 18,835−0.6%100% | 18,947—100% | |
| Accounts payable | 3,343−30.5%6.3% | 4,811+72.3%7.7% | 2,793−49.4%5.2% | 5,521+460083233%9.7% | 0.0−99.8%0.0% | 0.7r697−99.9%0.0% | 1,104+6.1%3.0% | 1,041+25.6%3.1% | 829+47.2%4.4% | 563r563—3.0% | |
| Current liabilities | 4,722−19.8%8.9% | 5,885+39.7%9.5% | 4,212−45.3%7.8% | 7,697+29.1%13.6% | 5,963+22.8%18.5% | 4,856r4,856−24.9%17.3% | 6,468+7.4%17.5% | 6,024+23.8%18.1% | 4,867+33.1%25.8% | 3,657—19.3% | |
| Lease liabilities (non-current) | 209−47.5%0.4% | 398−33.2%0.6% | 596−28.2%1.1% | 830—1.5% | — | 812r812−27.2%2.9% | 1,116—3.0% | — | — | — | |
| Total liabilities | 4,941−22.0%9.3% | 6,338+30.2%10.2% | 4,868−43.8%9.1% | 8,666+39.2%15.3% | 6,225−4.4%19.3% | 6,514r6,514−27.0%23.3% | 8,923+31.4%24.2% | 6,791−5.1%20.4% | 7,155+94.8%38.0% | 3,673—19.4% | |
| Retained earnings | 5,715−57.5%10.8% | 13,434+97.9%21.6% | 6,787+7.7%12.6% | 6,302—11.1% | −17,942—−55.7% | −22,061r−22,061—−78.8% | −15,226—−41.2% | −13,526—−40.7% | −11,503—−61.1% | −7,792—−41.1% | |
| Shareholders' equity | 48,098−13.8%90.7% | 55,827+14.3%89.8% | 48,842+1.6%90.9% | 48,069+84.8%84.7% | 26,015+21.0%80.7% | 21,496r21,496−23.2%76.7% | 28,002r28,001+5.8%75.8% | 26,460+127%79.6% | 11,680−23.5%62.0% | 15,274—80.6% | |
| Total liabilities and equity | 53,039−14.7%100% | 62,165+15.7%100% | 53,710−5.3%100% | 56,735+76.0%100% | 32,240+15.1%100% | 28,010r28,010−24.1%100% | 36,925+11.0%100% | 33,251+76.5%100% | 18,835−0.6%100% | 18,947—100% | |
| Shares outstanding | 16−0.2%— | 16+0.7%— | 16−0.1%— | 16−1.4%— | 17+0.8%— | 16+0.0%— | 16+2.3%— | 16+19.5%— | 13−0.4%— | 14—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 400+100%1.5% | 200r239−27.3%0.5% | 275−12.7%1.1% | 315−48.6%0.7% | 613−15.1%2.3% | 722r722+32.3%7.5% | 546−17.1%2.0% | 658+69.7%2.5% | 388+14.9%1.9% | 338—2.3% | |
| Share-based compensation | 295−8.7%1.1% | 323−1.5%0.8% | 328+75.4%1.3% | 187−54.9%0.4% | 415+7.5%1.5% | 386r386−37.8%4.0% | 621−36.8%2.3% | 983+142%3.7% | 406−44.1%2.0% | 726—4.9% | |
| Cash from operating activities | 528—1.9% | −831—−2.0% | −2,145—−8.8% | −1,412—−3.2% | −286—−1.1% | −434r−434—−4.5% | −2,107—−7.7% | −8,564—−32.4% | −3,057—−14.8% | −851—−5.7% | |
| Capital expenditure | −196—−0.7% | −276—−0.7% | −229—−0.9% | −159—−0.4% | −128—−0.5% | −359r−359—−3.7% | −401—−1.5% | −855—−3.2% | −288—−1.4% | −286—−1.9% | |
| Cash from investing activities | −196—−0.7% | −276—−0.7% | −187−101%−0.8% | 14,841+11405%33.3% | 129−98.2%0.5% | 7,030r7,031—73.4% | −4,898—−18.0% | −2,642−143%−10.0% | 6,174—30.0% | −7,852—−53.0% | |
| Shares bought back | −300—−1.1% | — | −27—−0.1% | −2,999—−6.7% | — | — | — | — | — | — | |
| Cash from financing activities | −305−2133%−1.1% | 15—0.0% | −40—−0.2% | −2,428—−5.5% | −231−209%−0.9% | 211r210−91.9%2.2% | 2,620−80.7%9.6% | 13,605+606%51.5% | 1,926−77.8%9.4% | 8,681—58.6% | |
| Change in cash | — | — | — | — | — | — | −4,384−283%−16.1% | 2,399−52.4%9.1% | 5,043—24.5% | −23—−0.2% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 16,618−53.3%100% | 5,995−12.9%100% | 2,290−68.7%100% | 3,394−59.3%100% | 4,939*−62.2%100% | 6,884−22.1%100% | 7,315−20.8%100% | 8,344−21.7%100% | 13,066*+4.0%100% | 8,839—100% | 9,239—100% | 10,663—100% | 12,567*—100% | |
| Cost of revenue | 9,673−47.8%58.2% | 2,707−35.1%45.2% | 1,521−65.5%66.4% | 2,403−39.8%70.8% | 3,042*−49.0%61.6% | 4,171+15.9%60.6% | 4,412+15.6%60.3% | 3,990−0.3%47.8% | 5,960*+25.8%45.6% | 3,599—40.7% | 3,816—41.3% | 4,001—37.5% | 4,736*—37.7% | |
| Gross profit | 6,945−59.3%41.8% | 3,288+21.2%54.8% | 769−73.5%33.6% | 991−77.2%29.2% | 1,897*−73.3%38.4% | 2,713−48.2%39.4% | 2,903−46.5%39.7% | 4,354−34.6%52.2% | 7,106*−9.3%54.4% | 5,240—59.3% | 5,423—58.7% | 6,662—62.5% | 7,831*—62.3% | |
| Research and development | 5,687−23.7%34.2% | 1,106−39.2%18.4% | 1,109−24.6%48.4% | 1,590−39.0%46.8% | 1,882*+20.6%38.1% | 1,819+111%26.4% | 1,471+69.9%20.1% | 2,606+181%31.2% | 1,561*+131%11.9% | 863—9.8% | 866—9.4% | 926—8.7% | 677*—5.4% | |
| Selling, general and administrative | 7,844−8.0%47.2% | 2,253+17.5%37.6% | 1,786−10.1%78.0% | 2,043−7.5%60.2% | 1,762*−27.1%35.7% | 1,917+21.9%27.8% | 1,986+25.8%27.1% | 2,208+39.8%26.5% | 2,416*—18.5% | 1,573—17.8% | 1,579—17.1% | 1,579—14.8% | — | |
| Selling and marketing | 5,719−12.3%34.4% | 1,548+0.1%25.8% | 1,054−24.1%46.0% | 1,716−21.5%50.6% | 1,401*−0.1%28.4% | 1,546+18.1%22.5% | 1,389+39.5%19.0% | 2,186+72.1%26.2% | 1,403*+124%10.7% | 1,309—14.8% | 996—10.8% | 1,270—11.9% | 625*—5.0% | |
| General and administrative | — | — | — | — | — | — | — | — | — | 1,573—17.8% | 1,579—17.1% | 1,579—14.8% | 952*—7.6% | |
| Operating expenses | 19,250−14.5%116% | 4,907−7.1%81.9% | 3,949−18.5%172% | 5,349−23.6%158% | 5,045*−6.2%102% | 5,282+41.0%76.7% | 4,846+40.8%66.2% | 7,000+85.4%83.9% | 5,380*+139%41.2% | 3,745—42.4% | 3,441—37.2% | 3,775—35.4% | 2,254*—17.9% | |
| Operating income | −12,305—−74.0% | −1,619—−27.0% | −3,180—−139% | −4,358—−128% | −3,148*−282%−63.7% | −2,569−272%−37.3% | −1,943−198%−26.6% | −2,646−192%−31.7% | 1,726*−69.1%13.2% | 1,495—16.9% | 1,982—21.5% | 2,887—27.1% | 5,577*—44.4% | |
| Interest and finance income | — | — | — | — | — | — | — | — | — | 279—3.2% | 209—2.3% | 214—2.0% | — | |
| Interest expense and finance costs | — | — | — | — | — | — | −183—−2.5% | −184—−2.2% | — | — | −209—−2.3% | −214—−2.0% | — | |
| Net interest income | 523−30.9%3.1% | 126−21.3%2.1% | 117−36.1%5.1% | 125−32.1%3.7% | 155*−32.6%3.1% | 160−42.7%2.3% | 183—2.5% | 184—2.2% | 230*—1.8% | 279—3.2% | — | — | — | |
| Other non-operating income (expense) | 523−30.9%3.1% | 126−21.3%2.1% | 117−36.1%5.1% | 125−32.1%3.7% | 155*−32.6%3.1% | 160−42.7%2.3% | 183−12.4%2.5% | 184−14.0%2.2% | 230*+0.9%1.8% | 279—3.2% | 209—2.3% | 214—2.0% | 228*—1.8% | |
| Income before tax | −11,782—−70.9% | −1,493—−24.9% | −3,063—−134% | −4,233—−125% | −2,993*−253%−60.6% | −2,409−236%−35.0% | −1,760−180%−24.1% | −2,462−179%−29.5% | 1,956*−66.3%15.0% | 1,774—20.1% | 2,191—23.7% | 3,101—29.1% | 5,805*—46.2% | |
| Income tax | 4,253—25.6% | 0*—0.0% | 5,686—248% | −1,607−1561%−47.3% | 174*−57.6%3.5% | −1,466−362%−21.3% | −723−225%−9.9% | 110−86.7%1.3% | 410*−74.3%3.1% | 559—6.3% | 579—6.3% | 827—7.8% | 1,595*—12.7% | |
| Net income attributable to shareholders | −16,035—−96.5% | −1,493—−24.9% | −8,749—−382% | −2,626—−77.4% | −3,167*−305%−64.1% | −943−178%−13.7% | −1,037−164%−14.2% | −2,572−213%−30.8% | 1,546*−63.3%11.8% | 1,215—13.7% | 1,612—17.4% | 2,274—21.3% | 4,210*—33.5% | |
| Earnings per share, basic | — | -0.09—— | -0.53—— | -0.16—— | — | -0.06−186%— | -0.06−160%— | -0.16−214%— | — | 0.07—— | 0.10—— | 0.14—— | — | |
| Earnings per share, diluted | — | -0.09—— | -0.53—— | -0.16—— | — | -0.06−186%— | -0.06−160%— | -0.16−214%— | — | 0.07—— | 0.10—— | 0.14—— | — | |
| Shares, weighted average (basic) | 16+0.9%— | 16+0.9%— | 16+0.9%— | 16+0.7%— | — | 16−0.0%— | 16+0.1%— | 16+0.3%— | — | 16—— | 16—— | 16—— | — | |
| Shares, weighted average (diluted) | 16+0.9%— | 16+0.9%— | 16+0.9%— | 16+0.7%— | — | 16−0.2%— | 16−0.1%— | 16+0.1%— | — | 16—— | 16—— | 16—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 12,920—31.9% | 12,920−47.2%31.9% | 15,186−31.5%36.8% | 18,327−3.9%35.6% | 22,083+0.1%41.6% | 24,453+8.4%41.9% | 22,162+16.8%37.7% | 19,072+29.5%31.7% | 22,056−4.7%35.5% | 22,558—37.7% | 18,972—32.6% | 14,728—25.7% | 23,148—43.1% | |
| Receivables | 1,403—3.5% | 1,403−85.0%3.5% | 1,680−86.7%4.1% | 3,578−80.1%6.9% | 6,041−69.4%11.4% | 9,336−45.0%16.0% | 12,622−31.0%21.4% | 18,018−8.2%29.9% | 19,731+85.4%31.7% | 16,961—28.3% | 18,293—31.5% | 19,625—34.3% | 10,645—19.8% | |
| Inventory | 17,965—44.3% | 17,965+37.8%44.3% | 18,459+48.8%44.7% | 16,500+66.3%32.0% | 14,563+44.2%27.5% | 13,040+9.0%22.4% | 12,405−2.9%21.1% | 9,923−32.6%16.5% | 10,097−14.9%16.2% | 11,968—20.0% | 12,769—22.0% | 14,720—25.7% | 11,861—22.1% | |
| Other current assets | 1,687—4.2% | 1,687−17.1%4.2% | 1,745−25.7%4.2% | 1,707+11.4%3.3% | 1,683+11.7%3.2% | 2,035+27.5%3.5% | 2,349+112%4.0% | 1,533+31.1%2.5% | 1,507+69.7%2.4% | 1,596—2.7% | 1,106—1.9% | 1,169—2.0% | 888—1.7% | |
| Current assets | 34,584—85.3% | 34,584−31.1%85.3% | 37,677−27.8%91.3% | 42,590−21.4%82.6% | 45,892−19.1%86.5% | 50,205−8.4%86.1% | 52,219−4.1%88.7% | 54,196+0.5%90.0% | 56,738+14.6%91.3% | 54,806—91.6% | 54,473—93.7% | 53,913—94.1% | 49,528—92.2% | |
| Property, plant and equipment | 2,662—6.6% | 2,662+5.6%6.6% | 2,748+1.3%6.7% | 2,314−13.6%4.5% | 1,976−1.1%3.7% | 2,522+54.3%4.3% | 2,714+281%4.6% | 2,678+323%4.4% | 1,997+330%3.2% | 1,635—2.7% | 712—1.2% | 633—1.1% | 464—0.9% | |
| Right-of-use (leased) assets | 265—0.7% | 265−48.3%0.7% | 329−42.7%0.8% | 390−38.4%0.8% | 452−22.2%0.9% | 513−18.6%0.9% | 574−15.5%1.0% | 633−12.8%1.1% | 581−24.9%0.9% | 630—1.1% | 679—1.2% | 726—1.3% | 774—1.4% | |
| Total assets | 40,551—100% | 40,551−30.4%100% | 41,259−29.9%100% | 51,546−14.4%100% | 53,039−14.7%100% | 58,295−2.6%100% | 58,852+1.2%100% | 60,210+5.1%100% | 62,165+15.7%100% | 59,858—100% | 58,163—100% | 57,273—100% | 53,710—100% | |
| Accounts payable | 3,746—9.2% | 3,746−33.3%9.2% | 3,167−41.0%7.7% | 4,692−16.7%9.1% | 3,343−30.5%6.3% | 5,619+41.4%9.6% | 5,365+63.4%9.1% | 5,635+52.2%9.4% | 4,811+72.3%7.7% | 3,973—6.6% | 3,284—5.6% | 3,703—6.5% | 2,793—5.2% | |
| Current liabilities | 5,111—12.6% | 5,111−24.9%12.6% | 4,327−32.5%10.5% | 5,859−12.9%11.4% | 4,722−19.8%8.9% | 6,803+30.6%11.7% | 6,413+37.0%10.9% | 6,725+22.9%11.2% | 5,885+39.7%9.5% | 5,210—8.7% | 4,682—8.0% | 5,473—9.6% | 4,212—7.8% | |
| Lease liabilities (non-current) | — | — | 69−79.9%0.2% | 141−65.4%0.3% | 209−47.5%0.4% | 277−38.6%0.5% | 343−31.8%0.6% | 408−26.2%0.7% | 398−33.2%0.6% | 451—0.8% | 503—0.9% | 553—1.0% | 596—1.1% | |
| Total liabilities | 5,111—12.6% | 5,111−28.0%12.6% | 4,396−35.2%10.7% | 6,004−16.3%11.6% | 4,941−22.0%9.3% | 7,101+24.0%12.2% | 6,788+29.0%11.5% | 7,176+18.3%11.9% | 6,338+30.2%10.2% | 5,727—9.6% | 5,262—9.0% | 6,066—10.6% | 4,868—9.1% | |
| Retained earnings | −7,153—−17.6% | −7,153−181%−17.6% | −5,660−158%−13.7% | 3,089−71.6%6.0% | 5,715−57.5%10.8% | 8,882−25.3%15.2% | 9,825−7.9%16.7% | 10,862+19.9%18.0% | 13,434+97.9%21.6% | 11,888—19.9% | 10,673—18.4% | 9,061—15.8% | 6,787—12.6% | |
| Shareholders' equity | 35,440—87.4% | 35,440−30.8%87.4% | 36,863−29.2%89.3% | 45,542−14.1%88.4% | 48,098−13.8%90.7% | 51,194−5.4%87.8% | 52,064−1.6%88.5% | 53,034+3.6%88.1% | 55,827+14.3%89.8% | 54,131—90.4% | 52,901—91.0% | 51,207—89.4% | 48,842—90.9% | |
| Total liabilities and equity | 40,551—100% | 40,551−30.4%100% | 41,259−29.9%100% | 51,546−14.4%100% | 53,039−14.7%100% | 58,295−2.6%100% | 58,852+1.2%100% | 60,210+5.1%100% | 62,165+15.7%100% | 59,858—100% | 58,163—100% | 57,273—100% | 53,710—100% | |
| Shares outstanding | 16—— | 16+0.1%— | 16+0.1%— | 16+0.1%— | 16−0.2%— | 16+0.3%— | 16+0.3%— | 16+0.3%— | 16+0.7%— | 16—— | 16—— | 16—— | 16—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 363+10.3%2.2% | 81−17.3%1.4% | 86−13.1%3.8% | 96+11.6%2.8% | 100*+117%2.0% | 98+84.9%1.4% | 99+219%1.4% | 86+22.9%1.0% | 46r85*−22.0%0.4% | 53*—0.6% | 31*—0.3% | 70—0.7% | 59*—0.5% | |
| Share-based compensation | 286+38.8%1.7% | 70*—1.2% | 70*+1300%3.1% | 70−11.4%2.1% | 76*−37.7%1.5% | 0—0.0% | 5.0+400%0.1% | 79−13.2%0.9% | 122*+135%0.9% | 0—0.0% | 1.0—0.0% | 91—0.9% | 52*—0.4% | |
| Cash from operating activities | −11,354−695%−68.3% | −2,261*−199%−37.7% | −3,133*−201%−137% | −3,753—−111% | −2,207*—−44.7% | 2,295*−41.9%33.3% | 3,117*−26.3%42.6% | −2,677—−32.1% | −827*−131%−6.3% | 3,953*—44.7% | 4,230*—45.8% | −8,187—−76.8% | 2,668*—21.2% | |
| Capital expenditure | −174—−1.0% | −5.0*—−0.1% | −8.0*—−0.3% | −3.0—−0.1% | −158*—−3.2% | −4.0*—−0.1% | −27*—−0.4% | −7.0—−0.1% | — | −337*—−3.8% | −3.0*—−0.0% | −233—−2.2% | 0*—0.0% | |
| Cash from investing activities | −174−167%−1.0% | −5.0*—−0.1% | −8.0*—−0.3% | −3.0—−0.1% | −158*−153%−3.2% | −4.0*—−0.1% | −27*—−0.4% | −7.0—−0.1% | 297*—2.3% | −337*—−3.8% | −3.0*—−0.0% | −233—−2.2% | 0*—0.0% | |
| Shares bought back | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −300—−3.6% | — | — | — | — | 0*—0.0% | |
| Cash from financing activities | — | — | — | — | −5.0*−118%−0.1% | 0*—0.0% | 0*—0.0% | −300—−3.6% | 28*—0.2% | −30*—−0.3% | — | — | −7.0*—−0.1% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Sensus Healthcare, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$20 M72%-46%
- Service Revenue$3 M13%+8.1%
- Service(total)$3 M9.3%+30%
- Product Revenue$2 M6.3%+588%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Sensus Healthcare, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Sensus Healthcare, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Auditor changed 2 · Directors and officers 5 · Material agreement 1 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Sensus Healthcare, Inc.#
$120 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues6 reports
Lobbying firms hired in 2025
CAPITOL ADVOCACY & GOVERNMENT AFFAIRS, LLC $70 K · Brian Glackin & Associates LLC $50 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2025 | $120 K | — | 6 |
| 2020 | $80 K | — | 2 |
| 2019 | $200 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Sensus Healthcare”, “Capitol Advocacy & Government Affairs, LLC (On Behalf of Sensus Healthcare)” and “Sensus Healthcare, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
Product recalls by Sensus Healthcare, Inc.#
1 recalls since 2015, 23 units in the notices that give a number. Medical devices (FDA): 1.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Sensus Healthcare Inc, SRT-100 Vision IPX 0, HFUS Module IPX 1, with software version 1.9.2; Superficial X-ray Radiation Therapy System with Ultrasonic Imaging CapabilitiesWhen the user pauses the beam delivery, the dose timer is reset (to zero), and as a result may deliver an unexpected dose to the patient.Medical devicesClass II | 23 | Z-1235-2023 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
How Sensus Healthcare, Inc. compares in Medical Devices
- Market cap$49 M · higher than 28% of 142
- Revenue$27 M · higher than 22% of 155
- Net margin-88.5% · higher than 16% of 144
- Revenue growth-34.3% · higher than 4% of 104
- Price / sales2.8× · lower than 52% of 96
- Price / book1.0× · lower than 86% of 99
- FCF yield0.7% · higher than 63% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sensus Healthcare, Inc.🇺🇸 | $49 M | — | -88.5% | -34.3% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sensus Healthcare, Inc.? Verify and update this profile — free
Show Sensus Healthcare, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.